Group 1 - The forum "Phoenix Bay Area Finance Forum 2025" was held in Guangzhou, focusing on the theme "New Pattern, New Path" and gathering global political, business, and academic elites to explore development opportunities [1] Group 2 - The chairman of Guangzhou Xiangxue Pharmaceutical Co., Ltd., Wang Yonghui, emphasized the revolutionary opportunities that artificial intelligence (AI) and big data technologies bring to the development of traditional Chinese medicine (TCM), promoting its scientific and international progress [3] - Wang pointed out that TCM is fundamentally a data science, but the traditional reliance on individual experiences of renowned doctors has limitations such as insufficient data volume and unstable effects, making it difficult to undergo scientific validation [3] - He noted that the long-standing transmission of TCM has been constrained by human contact, lifespan, and experience, with the current era of big data and AI capable of addressing these shortcomings [3] - Wang believes that TCM is an ideal application scenario for AI, as technological innovations provide strong support for the personalized diagnosis and treatment advantages of TCM [4] - He explained that large models align well with the dialectical logic of TCM, processing knowledge from vast data to holistic models, allowing for reasoning that captures non-linear associations [3] - The output from these models is dynamic and personalized, resulting in "fuzzy correctness" rather than purely logical data relationships [3] Group 3 - Through AI empowerment, TCM is breaking through the limitations of experiential "black box" phenomena, achieving precision and intelligence in diagnosis and treatment, ultimately leading to significant improvements in therapeutic effects and continuous evolution [4] - Wang expressed confidence that as therapeutic effects continue to improve, TCM will gain widespread recognition globally and shine in the field of human health [4]

Group 1 - The "Phoenix Bay Area Finance Forum 2025" was held in Guangzhou on September 23-24, focusing on the theme "New Pattern, New Path" and gathering global political, business, and academic elites to explore development opportunities [1] Group 2 - Wang Yonghui, Chairman of Guangzhou Xiangxue Pharmaceutical Co., Ltd., emphasized the spirit and aspirations of Chinese enterprises in the globalization process during his keynote speech [3] - He highlighted the explosive growth of Chinese biomedicine going abroad, with this year's overseas scale exceeding $80 billion, transitioning from simple product exports to intellectual property exports [3] - Wang pointed out that Traditional Chinese Medicine (TCM) represents unique Chinese cultural and medical resources, and it is currently facing a historic opportunity for internationalization [3] - He illustrated TCM's global influence, stating that "TCM is medicine for humanity, belonging to China and the world, as it is a shared wealth of all mankind" [3] - Despite its potential, he acknowledged that TCM's actual application in medicine remains limited, indicating that true acceptance and integration into global healthcare is still a distant goal [3]

Market Overview - The Chinese medicine sector experienced a decline of 0.57% on September 22, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Tianmu Pharmaceutical: closed at 18.31, up 2.29% with a trading volume of 35,700 shares [1] - Fangsheng Pharmaceutical: closed at 11.02, up 2.23% with a trading volume of 186,100 shares [1] - Jiuzi Tang: closed at 10.34, up 1.77% with a trading volume of 169,900 shares [1] - Conversely, Zhongsheng Pharmaceutical saw a significant decline, closing at 18.52, down 6.28% with a trading volume of 974,000 shares [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 429 million yuan from institutional investors, while retail investors saw a net inflow of 392 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors remained active [2] Individual Stock Capital Flow - Key stocks with notable capital flow include: - Zhendong Pharmaceutical: net inflow of 31.47 million yuan from institutional investors [3] - Daren Tang: net inflow of 27.08 million yuan from institutional investors [3] - Jiuzi Tang: net inflow of 18.17 million yuan from institutional investors [3] - Stocks like Daren Tang and Jiuzi Tang experienced negative net inflows from retail investors, indicating a divergence in investor sentiment [3]

Core Viewpoint - The article discusses the rising interest in Chinese metaphysics, such as Feng Shui and AI fortune-telling, particularly among Western audiences, highlighting a cultural shift towards spiritual and emotional well-being in response to economic challenges [2][8][14]. Group 1: Cultural Phenomenon - The trend of using Feng Shui in business decisions is spreading among car manufacturers in China, with companies choosing locations for press conferences based on perceived metaphysical benefits [1]. - This fascination with metaphysics is not unique to the automotive industry; it is prevalent among wealthy individuals in Hong Kong and real estate developers in mainland China, who incorporate Feng Shui principles into their projects [2]. - The phenomenon has also gained traction internationally, with TikTok's fengshui topic surpassing 3 billion views, indicating a growing interest in these concepts among young people in the West [2][3]. Group 2: AI and Fortune-Telling - AI applications like FateTell are emerging, offering services such as BaZi fortune-telling to overseas users, particularly targeting young women interested in Eastern culture [6]. - FateTell's products, "Book of Destiny" and "Book of Luck," are priced at $39.99 and $19.99, respectively, with a notable user repurchase rate of 30% [6]. - The global metaphysical application market is projected to reach $180.18 billion in 2024, with expectations to exceed $249 billion by 2032, highlighting the significant growth potential in this sector [8]. Group 3: Supply Chain and Product Pricing - The crystal industry in Jiangsu, China, is capitalizing on the demand for metaphysical products, with items that cost only a few dollars in China selling for thousands in overseas markets [9][12]. - For instance, a purple crystal tree sold by Karma and Luck retails for $2,000 abroad, while the same product costs around 20.9 yuan in China, showcasing a price markup of nearly 46 times [12]. - Buddha Stones, another brand, integrates Tibetan Buddhist elements into modern designs, achieving annual sales exceeding $8 million with a product markup of over 30 times [12]. Group 4: Market Challenges and Strategies - Despite the growing interest, Chinese metaphysical products face challenges in establishing a robust market presence compared to established systems in Japan and India [13]. - Chinese sellers are adapting by rebranding concepts like Feng Shui as "spatial energy science" and BaZi as "personality and destiny analysis" to make them more palatable to Western consumers [14][15]. - The emotional value associated with these products is significant, with surveys indicating that 43% of American adults own spiritual or faith-related items, and 30% use them daily [19].

Core Viewpoint - The "Phoenix Bay Area Financial Forum 2025" will be held in Guangzhou on September 23-24, focusing on the reconstruction of global economic and trade order, industrial and financial transformation, and the cultivation of new driving forces for development in the Guangdong-Hong Kong-Macao Greater Bay Area [1][26]. Group 1: Forum Themes and Key Discussions - The forum will address the profound changes in the global economic landscape, driven by rule reconstruction, geopolitical competition, and technological revolutions, leading to a reshaping of economic order [1][2]. - Keynote speeches will be delivered by prominent figures, including former officials and experts, discussing the new global economic order and the driving factors behind its formation [2][3]. - A special session on "New Paths for Corporate Globalization" will feature discussions on high-quality and sustainable overseas expansion strategies for companies in complex environments [2][3]. Group 2: Digital Technology and Financial Systems - Digital technology is recognized as a core force in reshaping financial systems, with discussions on the acceleration of central bank digital currency (CBDC) development and the regulatory framework for private digital currencies [3][4]. - The forum will explore the evolution of digital financial infrastructure and the opportunities and challenges it presents [3][4]. Group 3: Investment Opportunities in China - The forum will examine whether China is entering a new growth cycle amid the restructuring of global capital flows and economic transformation [4]. - Discussions will include macro trends and investment practices, focusing on the revaluation logic of Chinese assets [4]. Group 4: Awards and Recognition - The "2025 Phoenix Star Listed Company Awards" will take place on September 23, evaluating companies based on five dimensions: market value management, reputation management, human-centered management, innovation management, and globalization [5]. - This award aims to provide investors with in-depth analysis beyond financial metrics and encourage companies to achieve balanced development [5].

Core Viewpoint - The biopharmaceutical industry is a key sector in the new global technological revolution and competition, with Huangpu District in Guangzhou transforming from a "follower" to a "leader" in this field, showcasing China's robust capabilities in biopharmaceutical innovation [1][4]. Industry Overview - The biopharmaceutical industry in Huangpu has grown to a scale exceeding 240 billion yuan, with over 4,800 enterprises, and the traditional Chinese medicine (TCM) sector is projected to reach an industrial output value of 5.2 billion yuan by 2024 [3][4]. - Huangpu has a total of 1,243 TCM product approvals, accounting for 37% of the city and 11% of the province, indicating a strong foundation for innovation [4]. Development Initiatives - Huangpu has launched the "1369 Project" to promote the integration of TCM with modern medical practices and industry, aiming to create a model for TCM innovation and development [5][12]. - The district is focusing on the dual development of TCM and intelligent medical equipment, with significant government support for projects that enhance TCM's industrialization and modernization [5][10]. Talent and Education - Huangpu is implementing a "Pu Ju Ming TCM" initiative to attract renowned TCM practitioners and establish a mentorship system to cultivate a new generation of TCM professionals [12][13]. - The district is also fostering interdisciplinary talent that combines traditional medical knowledge with modern technological skills, essential for advancing TCM practices [13][14]. Technological Integration - The integration of artificial intelligence (AI) in TCM is being explored, with the development of intelligent diagnostic tools and treatment systems, which are expected to revolutionize the industry [10][11]. - Huangpu has established a collaborative framework for TCM research and development, focusing on the commercialization of traditional formulations and enhancing the efficiency of new drug development [6][9]. Market Trends - There is a growing demand for TCM services, with 40% of patients in Huangpu opting for TCM treatments, reflecting a robust and efficient service system [12][14]. - The district is actively working to improve the conversion efficiency of hospital-based formulations into marketable TCM products, leveraging local enterprises for innovation [9][14].

Market Overview - On September 17, the Chinese medicine sector fell by 0.19%, with Darentang leading the decline [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Xiangxue: Closed at 11.49, up 8.29% with a trading volume of 289,200 shares and a turnover of 320 million yuan [1] - Enwei Pharmaceutical: Closed at 34.98, up 3.49% with a trading volume of 18,300 shares and a turnover of 63.37 million yuan [1] - Major decliners included: - Darentang: Closed at 44.44, down 2.39% with a trading volume of 78,900 shares and a turnover of 35.2 million yuan [2] - ST Changyao: Closed at 3.92, down 2.00% with a trading volume of 102,100 shares and a turnover of 39.94 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 593 million yuan from institutional investors, while retail investors saw a net inflow of 527 million yuan [2][3] - The table of capital flow indicates that: - Jilin Aodong had a net inflow of 18.77 million yuan from institutional investors, but a net outflow from retail investors [3] - ST Xiangxue also saw a net inflow from institutional investors but a significant outflow from retail investors [3]

Market Overview - The Shanghai Composite Index closed at 3877.55 points, with a change of 0.41% [1] - The total trading volume of A-shares reached 1561.918 billion yuan [1] Technical Analysis - A total of 127 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - COFCO Technology: 5-day MA at 11.41 yuan, 10-day MA at 11.52 yuan, difference of -0.92% [1] - Jiuri New Materials: 5-day MA at 27.35 yuan, 10-day MA at 27.59 yuan, difference of -0.86% [1] - Potential Energy Trust: 5-day MA at 20.44 yuan, 10-day MA at 20.59 yuan, difference of -0.77% [1] Individual Stock Performance - COFCO Technology: Today's change of 0.09%, trading volume of 1.13% [1] - Jiuri New Materials: Today's change of 1.49%, trading volume of 1.84% [1] - Potential Energy Trust: Today's change of 0.34%, trading volume of 1.64% [1] - Other notable stocks with death crosses include: - Tongzhou Electronics: Today's change of -0.42%, trading volume of 2.40% [1] - ST Long Pharmaceutical: Today's change of -2.50%, trading volume of 2.14% [1] - Jin Hong Shun: Today's change of -1.44%, trading volume of 2.07% [1]

为进一步加强与投资者的互动交流，广州市香雪制药股份有限公司（以下简 称"公司"）将参加由中国证券监督管理委员会广东监管局、广东上市公司协会 联合举办的"向新提质 价值领航--2025 年广东上市公司投资者关系管理月投资 者集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周 五）15:30-17:00。 届时公司高管将在线就 2025 年半年度业绩、公司治理、发展战略、经营状 况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与！ 广州市香雪制药股份有限公司 关于参加广东辖区 2025 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码:300147 证券简称: ST 香雪 公告编号:2025-044 特此公告。 广州市香雪制药股份有限公司董事会 2025 年 9 月 16 日 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.37% on September 15, with ST Xiangxue leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index rose by 0.63% to 13005.77 [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Wanbangde (002082) with a closing price of 11.33, up 10.00% [1] - Kangmei Pharmaceutical (600518) at 2.18, up 4.81% [1] - Zhongheng Group (600252) at 2.88, up 3.97% [1] - Conversely, ST Xiangxue (300147) saw a significant decline of 4.39%, closing at 10.66 [2] - Other notable decliners included: - Enwei Pharmaceutical (301331) down 3.25% [2] - Zhendong Pharmaceutical (300158) down 2.97% [2] Trading Volume and Capital Flow - The Chinese medicine sector recorded a net outflow of 470 million yuan from institutional investors, while retail investors saw a net inflow of 398 million yuan [2] - The trading volume for major stocks included: - Kangmei Pharmaceutical with a trading volume of 9.5463 million shares and a transaction value of 2.086 billion yuan [1] - Wanbangde with a trading volume of 414,700 shares and a transaction value of 448 million yuan [1] Capital Inflow Analysis - Major stocks with significant net inflows from institutional investors included: - Kangmei Pharmaceutical with a net inflow of 18.7 million yuan [3] - Wanbangde with a net inflow of 67.5 million yuan [3] - Conversely, stocks like Zhongheng Group and Panzhong Pharmaceutical experienced net outflows from institutional investors [3]